CRISPR is a tool that finds one exact spot in a person's DNA and changes it. Here is how, without any jargon.
Every cell in your body carries a set of instructions. The instructions are written in a four-letter alphabet: A, T, C and G. Strung together, they make about three billion letters.
Sections of that book are recipes. Each recipe tells the cell how to build one particular thing it needs, like the part of your blood that carries oxygen.
If a single letter in a recipe is wrong, the thing the cell builds can come out wrong. That is what a genetic disease is. Sickle cell disease, for example, comes from one wrong letter.
Bacteria get attacked by viruses. Over a very long time they developed a defence: when a bacterium survives an attack, it keeps a small piece of the virus, like a mugshot in a filing cabinet.
If that virus comes back, the bacterium pulls out the mugshot, uses it to find the virus, and cuts the virus apart.
Scientists noticed something. If the mugshot is what decides where the cutting happens, then you can swap the mugshot for anything you like, and the cutting will happen wherever you point it.
Two scientists, Emmanuelle Charpentier and Jennifer Doudna, worked out how to do exactly that. They won the Nobel Prize in Chemistry in 2020 for it. The prize committee called their tool "genetic scissors".
The tool has only two parts.
The scissors. A protein called Cas9. It can cut DNA, but on its own it has no idea where to cut.
The address. A short molecule called a guide. It carries a copy of the 20 letters you want to find. Snap it into the scissors and the scissors now have a destination.
Changing where you cut means changing those 20 letters. Nothing else about the tool changes. That is the whole reason CRISPR spread through laboratories so quickly: it is easy to aim.
Here is the part that surprises people. The scissors do not fix anything. They only cut. The repair is done by the cell itself, which treats a cut in its DNA as an emergency.
The cell has two ways to handle it.
Glue it back quickly. The cell grabs the two loose ends and joins them. It is fast and a bit careless, so a letter or two usually goes missing at the join. That garbles the recipe from that point on, and the recipe stops working. If your goal was to switch something off, that is exactly what you wanted.
Copy from a spare. If you also hand the cell a matching strip of DNA that carries the correct letter, the cell can copy from it while it repairs. That fixes the recipe properly. It works less often, but when it works, it is precise.
This is not a someday technology. A treatment called Casgevy was approved in the UK in November 2023 and in the US in December 2023, for sickle cell disease and a related blood condition. In July 2026 the US regulator extended it to children as young as two.
It works by a clever detour. Rather than fixing the broken recipe, it switches a different recipe back on: the version of the blood protein that you used before you were born, which does not have the defect. Doctors take out some of the patient's own cells, edit them, and put them back.
In 2025 a baby known as KJ, born with a rare liver condition, received a treatment designed for him alone, built in about six months. He is now walking, with mild symptoms of something that used to be fatal.
Getting it to the right place. The tool is large. Getting it inside the specific cells that need fixing, in a living body, is the biggest unsolved problem. The liver is reachable. Most other organs are not, yet.
Cutting in the wrong place. A spot that nearly matches the address can occasionally get cut too. This is checked carefully before any treatment is used.
Cost. Casgevy is priced at about 2.2 million US dollars per patient, and requires a hospital stay and harsh preparatory drugs.
If you want the same story with the real mechanism and a simulator you can step through, the intermediate version is the next stop.